Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Checkpoint-blockade treatments face significant primary and acquired resistance, limiting their clinical efficacy.
• Absence of T-cell infiltration into tumors is a key factor hindering immune checkpoint inhibitor effectiveness.
• Metastatic melanoma patients often require additional therapeutic strategies beyond current treatments.

Purpose of the Study:

• To investigate a combination therapy enhancing anti-tumor immune responses in metastatic melanoma.
• To assess the role of intratumoral IL-12 and anti-PD-1 in overcoming resistance to checkpoint blockade.
• To determine if IL-12 pre-treatment sensitizes tumors to anti-PD-1 therapy.

Main Methods:

• Utilized a metastatic B16F10 melanoma mouse model.
• Administered intratumoral plasmid IL-12 via electrotransfer in combination with anti-PD-1 therapy.
• Analyzed tumor-infiltrating lymphocytes (CD8+ and CD4+ T cells) and MHC-I expression on tumor cells.

Main Results:

• The combination therapy successfully increased tumor-infiltrating lymphocytes.
• Effective anti-tumor responses were dependent on CD8+ and CD4+ T cells.
• Combination treatment led to increased MHC-I surface expression on tumor cells, improving immune recognition.
• IL-12 activation sensitized tumors to subsequent anti-PD-1 treatment.

Conclusions:

• Combination of IL-12 and anti-PD-1 therapy is a promising strategy to overcome resistance in melanoma.
• Enhancing T-cell infiltration and MHC-I expression are critical mechanisms for improved therapeutic efficacy.
• This approach offers a potential therapeutic strategy to improve patient responses to checkpoint blockade therapy.